The number of new graduates hired for sales rep roles increased in FY2025 after declining for five consecutive years, a…
COMMENTARY
Sumitomo Dainippon Aims at 100 Billion Yen Sales from “Frontier Business,” Making Challenge Beyond Drugs
A growing number of drug makers are attempting to diversify their businesses by expanding into non-pharmaceutical sectors. Sumitomo Dainippon Pharma, which is one of these companies, aims to establish its “frontier business” as a growth engine of its midterm business…
To read the full story
Related Article
- Sumitomo Dainippon Predicts 20-30 Billion Yen Sales from “Frontier Business” by FY2027
September 10, 2021
- Sumitomo Dainippon Eyes 100 Billion Yen Sales from Frontier Biz: President
August 7, 2020
- Sumitomo Dainippon, Save Medical Link Up on Diabetes App; Approval Eyed in FY2022
August 6, 2020
- Sumitomo Dainippon, Aikomi Join Forces for Research on Medical Devices to Relieve BPSD
February 12, 2019
COMMENTARY
- New Grad Hires for Sales Reps Up after 5 Years of Decrease: FY2025 Survey
May 8, 2025
- How Will Japan Deal with Expected Cost Spike with Japan-Made Antibiotic APIs?
April 1, 2025
- Fair or Unfair? PMP Return Applied for First Time in Off-Year Revision
March 24, 2025
- Evolving GLP-1 Drugs: Could Double and Triple Agonists Achieve Blockbuster Status?
March 4, 2025
- New Govt Fund for Innovative Drugs: Twists, Turns, and Hope
February 10, 2025
The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…